Incyte Corp. (INCY)

Incyte Corp. Aktie (INCY) Neueste Nachrichten

Company News For May 14, 2024

Zacks Investment Research

Tech Stocks Inch Higher Ahead Of Key Inflation Data, GameStop Skyrockets, Tencent Fuels China Rally: What's Driving Markets Monday?

Benzinga

Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates

Zacks Investment Research

Incyte (INCY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks Investment Research

The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals

Zacks Investment Research

Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX

Zacks Investment Research

Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research

Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends

Benzinga

Peeling Back The Layers: Exploring Incyte Through Analyst Insights

Benzinga

Incyte (INCY) Earnings Expected to Grow: Should You Buy?

Zacks Investment Research

Incyte (INCY) to Report Q1 Earnings: What's in the Cards?

Zacks Investment Research

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

Zacks Investment Research

Novartis (NVS) to Undertake Job Cuts in Development Department

Zacks Investment Research

Agilent (A) is Set for Analytica 2024 With Advanced Products

Zacks Investment Research

Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up

Zacks Investment Research

Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?

Zacks Investment Research

Incyte (INCY) Posts Positive Results on Opzelura From HS Study

Zacks Investment Research

Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)

Benzinga

The Analyst Verdict: Incyte In The Eyes Of 8 Experts

Benzinga

Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates

Zacks Investment Research

Here's What Key Metrics Tell Us About Incyte (INCY) Q4 Earnings

Zacks Investment Research

Incyte (INCY) Lags Q4 Earnings and Revenue Estimates

Zacks Investment Research

Drug, Biotech Stocks' Q4 Earnings Due on Feb 13: BIIB, ZTS & INCY

Zacks Investment Research

Incyte (INCY) to Report Q4 Earnings: What's in the Cards?

Zacks Investment Research

Ahead of Incyte (INCY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Zacks Investment Research

Novartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology Drug

Zacks Investment Research

Incyte (INCY) Banks on Opzelura as Jakafi Faces Competition

Zacks Investment Research

IDEAYA Biosciences, Inc. (IDYA) Moves 7.6% Higher: Will This Strength Last?

Zacks Investment Research

Here are Wall Street’s favorite stocks in the sector expected to grow profits the most in 2024

MarketWatch

Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations

Benzinga

Here are Wall Street’s favorite stocks in the sector expected to grow profits the most in 2024

MarketWatch

Expert Ratings for Incyte

Benzinga

Wall Street Breakfast: The Week Ahead

Seeking Alpha

Sarepta Therapeutics (SRPT) Up 4.5% Since Last Earnings Report: Can It Continue?

Zacks Investment Research

Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?

Zacks Investment Research

Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug

Zacks Investment Research

MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis Study

Zacks Investment Research

Goldman Sachs Downgrades Incyte Amid Concerns Over Jakafi Studies, Competitiveness

Benzinga

The Latest Analyst Ratings for Incyte

Benzinga